$AQST

{"summary": "Author lays out a staged price-target roadmap for AQST tied to Anaphylm and Libervant regulatory and commercial catalysts through 2027-2028.", "reason": "The author provides a clear directional thesis (long) supported by a series of specific regulatory and commercial catalysts (Anaphylm resubmission, FDA filings, Libervant launch, etc.) linked to price targets.", "ideas": [{"symbol": "AQST", "direction": "long", "thesis": "The author is bullish on AQST, mapping a sequence of regulatory and commercial catalysts to escalating price levels. Anaphylm resubmission acceptance (late Q3/early Q4 '26) is seen driving $5.50-$6.00, FDA filing and clock-setting pushing $6.50-$7.25, and eventual Anaphylm US approval in '27 reaching $12-$16. Further catalysts include Canada NDS filing, Libervant US deal or solo launch, age-expansion PR, EU MAA filing, and AQST-108 data, with the author expecting high-teens to $20s on 7-product royalties and insurance uptake. Main risk is that these are speculative targets dependent on regulatory and commercial execution.", "thesis_short": "AQST staged catalysts drive multi-year upside", "quote": "Anaphylm resubmission accepted — late Q3 / early Q4 ’26 — $5.50–$6.00", "confidence": 0.7, "sentiment": 0.8, "timeframe": "through 2027-2028"}], "model": "gemini-3.1-flash-lite", "failure_count": 0, "verified": true, "extraction_model": "deepseek-flash"}